Glenmark receives approval for Ryaltris
Glenmark received the marketing approval from the Therapeutic Goods Administration (TGA), Australia for Ryaltris.
Ryaltris (olopatadine hydrochloride 665 mcg and mometasone furoate 25 mcg) is a fixed dose combination nasal spray of an antihistamine and a steroid, indicated for treating the symptoms associated with Allergic Rhinitis (AR) and rhinoconjunctivitis in patients aged 12 and over. Glenmark intends to commrcialize Ryaltris in several markets globally either on its own or through partnerships.
Seqirus, an Australia-based specialty biotechnology company CSL Ltd, entered into an exclusive licensing agreement with Glenmark’s subsidiary, Glenmark Specialty S.A., in July 2018 for commercializing Ryaltris in Australia. As per the terms, Glenmark will look after the product supply and Seqirus will be responsible for the regulatory filing and commercialization of the product in the country. Thus, Glenmark is entitled to receive commercial milestones payments from Seqirus. Ryaltris is set to be manufactured at Glenmark’s facility in Baddi in Himachal Pradesh.
Glenmark Pharmaceuticals Ltd (GPL) is a global innovative pharmaceutical company having operations globally and primarily focusing in the areas of oncology, respiratory, and dermatology. It has a significant presence in generic drugs market and has improved lives of millions of patients by offering safe and affordable medication for a period of time.
On Monday, the stock of the company closed at Rs 352.45, up by 0.74 per cent or Rs 2.60 per share. The 52-week high is Rs 706.90 and 52-week low is Rs 267.30 on the BSE.